Pfister B, Imhof P
Agents Actions. 1979 Jun;9(2):217-9. doi: 10.1007/BF02024738.
Of the vasodilators used at present in the treatment of heart failure, only nitroprusside and phentolamine inhibit platelet aggregation at therapeutic dose levels. The other vasodilators studied, viz. nitroglycerin, isosorbide dinitrate, hydrallazine, dihydrallazine and prazosin, only inhibit platelet aggregation at relatively high concentrations, well above those reached in vivo. The exact nature of the platelet receptor, stimulation and blockade of which respectively initiate and inhibit aggregation, is not yet know, but it would appear to resemble the presynaptic alpha-receptors of other tissues.
在目前用于治疗心力衰竭的血管扩张剂中，只有硝普钠和酚妥拉明在治疗剂量水平时抑制血小板聚集。所研究的其他血管扩张剂，即硝酸甘油、二硝酸异山梨醇酯、肼屈嗪、双肼屈嗪和哌唑嗪，仅在远高于体内所能达到的相对高浓度时才抑制血小板聚集。血小板受体的确切性质（分别刺激和阻断该受体可启动和抑制聚集）尚不清楚，但它似乎类似于其他组织的突触前α受体。
